Innocare
VerifiedA Chinese biopharmaceutical company that develops treatment for cancer and autoimmune diseases.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$369m (Public information from May 2024)
Share price
HKD5.14 9969.HK
Beijing China (HQ)
No columns specified